NIBIB’s role in the NIH HEAL Initiative
NIBIB is playing a major role in the National Institutes of Health (NIH) HEAL (Helping to End Addiction Long-termSM) Initiative, a trans-agency effort focused on improving prevention and treatment strategies for opioid misuse and addiction and enhancing pain management. Launched in April 2018 with funding from Congress, the HEAL Initiative brings new hope for people, families, and communities affected by the national opioid public health crisis.
Learn more about the NIH HEAL InitiativeSM.
Below are the research projects NIBIB is coordinating around the country.
Learn more about the NIH HEAL Initiative.
Funding Opportunity Announcements (FOAs)
HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)
HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)
HEAL Initiative Translational Devices to Treat Pain (U44 Clinical Trial Optional)
HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)
HEAL Initiative: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Anatomical and Functional Mapping of Pain-Related Visceral Organ Neural Circuitry (U01 Clinical Trial Optional)
Michael Wolfson, Ph.D., Program Director, NIBIB
Nick Langhals, Ph.D., Program Director, NINDS
Kari Ashmont, Ph.D., Health Program Specialist, NINDS
Eric Hudak, Ph.D., Scientific Program Manager, NINDS
Three webinars were held on December 2018 that introduced the audience to the funding opportunity announcements (FOAs), all seeking to develop medical devices to treat pain. These FOAs support different degrees of technological maturity. All focus on approaches that target the nervous system to provide the therapeutic, rehabilitative, or diagnostic capability.
Click here to download webinar slides.